Status:
COMPLETED
A Phase 3, Multi Site, Randomized, Double Blind, Placebo Controlled Study Of The Efficacy And Safety Comparing CP- 690,550 And Etanercept In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Lead Sponsor:
Pfizer
Conditions:
Psoriasis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
To evaluate the efficacy of CP-690,550 as compared to etanercept and the safety of CP-690,550 for treatment of moderate to severe chronic plaque psoriasis.
Eligibility Criteria
Inclusion
- Have had a diagnosis of plaque type psoriasis (psoriasis vulgaris);
- Have plaque-type psoriasis covering at least 10% of total body surface area
- Considered by dermatologist investigator to be a candidate for systemic therapy or phototherapy of psoriasis
Exclusion
- Non-plaque or drug induced forms of psoriasis
- Cannot discontinue current systemic and/or topical therapies for the treatment of psoriasis
- Cannot discontinue phototherapy
- Any uncontrolled significant medical condition
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2013
Estimated Enrollment :
1101 Patients enrolled
Trial Details
Trial ID
NCT01241591
Start Date
November 1 2010
End Date
January 1 2013
Last Update
December 26 2018
Active Locations (122)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro de Investigaciones Dermatologicas
Buenos Aires, C1114aap, Argentina
2
Centro de Investigaciones Dermatologicas
Buenos Aires, Argentina, C1114AAP
3
IMAI (Instituto Medico de Asistencia e Investigaciones)
Buenos Aires, Argentina, C1425AWC
4
LKH Feldkirch Abteilung fuer Dermatologie und Venerologie
Feldkirch, Austria, A-6807